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29.9%) vs 11.3% (11.1%–11.5%), adjusted OR = 2.09 (1.45–
3.02, p < 0.001)], and low HDL [54.5% (46.9%–62.0%) vs
29.4% (29.1%–29.7%), adjusted OR = 2.77 (2.02–3.80, p <
0.001)]. CONCLUSIONS: Compared with the general popula-
tion managed in BSA, MS prevalence was signiﬁcantly higher in
patients with BD, mainly due to higher prevalence of obesity;
high triglycerides and low HDL levels. These ﬁndings strongly
support the development of health policies addressing this health
problem in BD patients.
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OBJECTIVES: To estimate the prevalence of any type Bipolar
Disorder (BP) and comorbidity burden in a Health Management
Organization. METHODS: Cross-sectional assessment of the
Badalona Serveis Assistencials (BSA) administrative claim data-
base. All subjects above 15 years, both sexes, included in BSA
claim database were included in the analysis. Patients with BP,
diagnosed according with DSM-IV criteria formed the study
cohort. The control group was formed for the rest of individu-
als in the BSA database without BD. Prevalence of both BP dis-
order and comorbidities were assessed directly. Corresponding
odds ratios to measure intensity of association were computed
adjusted by age by using logistic regression techniques. The 
following comorbidities groups were assessed: diabetes, hyper-
tension, dyslipidemia, cancer, coronary hearth disease, cere-
brovascular disease, asthma, COPD, obesity, non-dementia
neurological disorders, dementia of any type, and other psychi-
atric disorders. RESULTS: We identiﬁed 178 subjects with BD
(53.4% women, 49.9 + 19.2 years old, mean + SD) out of 86.028
individuals [50,5% women (p = 0.494); 45.5 + 17.8 years (p =
0.001)] in BSA database; overall prevalence = 0.21% (0.18%–
0.24%), men [0.20% (0.17%–0.23%)], women [0.22%
(0.19%–0.25%)]. Patients with BD showed signiﬁcant higher
frequency of dislipidemia [25.8% (95% conﬁdence interval:
19.6%–32.9%) vs 16.2% (15.9%–16.5%); age adjusted OR =
1.54 (1.07–2.23, p = 0.021)], non dementia neurological disor-
ders [2.2% (0.6%–5.7%) vs 0.4% (0.3%–0.4%); adjusted OR
= 4.17 (1.50–11.60, p = 0.006)], dementia [9.0% (5.2%–14.2%)
vs 0.6% (0.5%–0.7%); adjusted OR = 14.00 (7.21–27.21, p <
0.001)], other psychiatric disorder [23.6% (17.6%–30.5%) vs
7.9% (7.7%–8.1%); adjusted OR = 3.29 (2.30–4.70, p < 0.001)]
and obesity [41.4% (32.3%–50.9%) vs 27.1% (26.6%–27.5%);
adjusted OR = 1.83 (1.24–2.68, p = 0.002)]. No other signiﬁ-
cant differences could be found. CONCLUSIONS: The observed
prevalence of Bipolar Disorders was comparable to the one
observed previously in other countries. Compared with general
population managed by BSA, the comorbidity burden is higher
in subjects with Bipolar Disorders, mainly any type neurological
disorders and other psychiatric disorder.
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OBJECTIVES: To correlate changes in negative symptoms of
schizophrenia, assessed by scores on the 16-item Negative
Symptom Assessment scale (NSA-16), with changes in scores on
various functional outcome scales. METHODS: Of 166 stable
outpatients with schizophrenia or schizoaffective disorder par-
ticipating in 1 of 3 medication or psychosocial intervention
studies, 99 had data at baseline and 9 months, and were included
in the analysis. The rating instruments used were the NSA-16,
Brief Psychiatric Rating Scale, and several functional outcome
rating scales: Quality of Life Scale (QLS), Multnomah Commu-
nity Ability Scale (MCAS), Global Assessment of Functioning
(GAF), Social and Occupational Functioning Assessment Scale
(SOFAS), Frontal Systems Behavioral Scale (FrSBe), Functional
Needs Assessment (FNA), and Life Skills Proﬁle (LSP). The asso-
ciation between change scores was assessed using Pearson’s cor-
relation coefﬁcients. RESULTS: Changes in negative symptoms
showed moderate to fairly strong correlations with changes
recorded on all functional outcome rating scales. The associations
were statistically signiﬁcant for all functional outcome measures,
including structured assessments (QLS: r = −0.423, P < 0.0001;
MCAS: r = −0.338, P = 0.0008), global assessments (GAF: r =
−0.521, P < 0.0001; SOFAS: r = −0.497, P < 0.0001), perfor-
mance-based assessments (FrSBe: r = 0.414, P = 0.0003; FNA: 
r = −0.231, P = 0.0247); and observational assessment (LSP: r =
−0.367, P = 0.0003). This pattern of association between reduc-
tions in negative symptoms and improvements in functional
outcome ratings was evident even after controlling for the effects
of treatment-related improvements in positive symptoms. CON-
CLUSIONS: Reductions in negative symptoms, as rated with the
NSA-16, are associated with improvements in clinician- and
patient-assessed functional outcomes measures. This association
is particularly strong when functional outcome is measured on
the QLS, GAF, and SOFAS. These ﬁndings suggest that treatments
that decrease negative symptoms may reduce the considerable
functional disability associated with schizophrenia.
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OBJECTIVES: To present three-months results on treatments
prescribed and their impact on the clinical aspects and Quality
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of Life (QoL) of children and adolescents with ADHD.
METHODS: ADORE, a 2-year, prospective, observational study
in Attention Deﬁcit/ Hyperactivity Disorder (ADHD) enrolling
patients across 10 European countries. ADORE main objective
is to describe the relationship between treatment prescribed and
QoL of ADHD, in actual practice, over a two-year period.
Patients were enrolled if in the opinion of the investigator
showed hyperactive/ inattentive/ impulsive symptoms. QoL was
measured with the Child Health and Illness Proﬁle (CHIP-CE).
Clinical ADHD speciﬁc and generic outcomes were measured
with ADHD-RS, CGI-Severity, SDQ, and CGAS. Other out-
comes included parent’s health problems, truancy, and social
invites. Treatments were classiﬁed as pharmacotherapy, psy-
chotherapy, pharmacotherapy and psychotherapy combination,
other, and none. All results presented are descriptive. Percentages
were calculated based on the number of patients who answered
the question of interest. RESULTS: A total of 1478 eligible
patients were analysed. Overall mean age (sd) for patients was
9.0 years (2.5), 84% of them being male. At baseline, 270
patients (19%) were prescribed psychotherapy, 360 (25%) phar-
macotherapy, 356 (25%) pharmacotherapy and psychotherapy
combination, 148 (10%) other therapy, and 294 (21%) nothing.
At 3 months, nearly 70% of the patients were receiving either
pharmacotherapy (442 [40.0%]) or its combination with psy-
chotherapy (310 [28.1%]). Baseline mean CGI-Severity score
(SD) was 4.4 (0.9) for the overall group with no major differ-
ences between the treatment regimens. At 3 months, the biggest
improvement was seen in the patients receiving pharmacother-
apy (−1.3 [1.1]) followed by combination (−1.1 [1.1]). Results
were consistent across scales (ADHD-RS, SDQ, CGAS, CHIP-
CE). CONCLUSIONS: Presented information suggests that, on
average, patient’s receiving pharmacotherapy or its combination
with psychotherapy experienced greater improvements over the
ﬁrst three months in the study.
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OBJECTIVES: The aim of this study was to evaluate the survival
of patients initiating hemodialysis (HD), and to analyze whether
low Health-Related Quality of Life (HRQoL) levels are predic-
tors of mortality in the short term, controlling certain variables
that had been shown in other studies to have a bearing on sur-
vival, and using scores, standardized for age and sex, of the
HRQoL measurement tool employed. METHODS: A multicen-
tric prospective study of all patients on HD in all the dialysis
units in Asturias, a region with a little over one million inhabi-
tants, from the 1st of January 2001 to the 30th September 2002.
A total of 199 patients initiated HD in our region and survived
the ﬁrst 3 months. A total of 137 patients who remained in HD
for at least three months had complete responses on HRQoL
measures, those that had received a transplant during the follow-
up were censored to survival analysis. RESULTS: It was observed
adjusted relative risk (RR) of death increased by 5% for each
year age increased; RR = 1.05 (CI 95% 1.01 1.09): p = 0.006,
in the same way that for each point that MCS increased, the
adjusted RR of death diminished 4%; RR = 0.96 (CI 95% 0.94
0.99); p = 0.006. CONCLUSIONS: Mental health has been
shown to be a factor independently associated with mortality; as
the MCS score worsens the adjusted relative risk of death of a
patient in HD increases.
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In routine clinical care, ADHD is rarely diagnosed in the adult
population in Germany. Little is known about actual care for
adult outpatients. To date, no pharmaceutical product has been
licensed in Germany for use in adult ADHD. OBJECTIVE: To
assess the (off-label) use of methylphenidate in this group of
patients, using the comprehensive medical claims database of
Nordbaden/Germany, covering an insured population of 2.234
m (or 2.7% of the German population), and hereof 1.766 m
adults, in 2003. METHODS: 630 adults with a diagnosis of
ADHD (ICD-10-codes F90.0, F90.1, “Hyperkinetic Disorder”)
were identiﬁed (administrative prevalence: 0.04%). For a retro-
spective analysis of methylphenidate prescriptions by gender and
coexisting conduct disorder, data from the organization of
licensed physicians (Kassenaerztliche Vereinigung) in Nord-
baden/Germany were combined with data from the regional
vdak, an association of statutory sick funds. RESULTS: One
third (34.6%) of adult patients with ADHD were treated (off-
label) with methylphenidate. Treatment prevalence was some-
what higher for males (39.4%, 95%-CI 31.3%–48.0%; cf.
females, 29.0%, 21.2%–37.9%). Patients with pure Hyperki-
netic Disorder (F90.0) appeared to be more likely (36.8%,
30.7%–43.3%) than patients with concomitant conduct 
disorder (F90.1: 14.8%, 4.2%–33.7%) to receive medication
(methylphenidate). Most methylphenidate prescriptions for adult
patients were written by psychiatrists and other mental health
care specialists (50% of DDDs) and by general practitioners
(31%). Adult patients accounted for 9% of the total number of
methylphenidate prescriptions for patients with ADHD in Nord-
baden. CONCLUSIONS: Besides the low administrative preva-
lence of adult ADHD in Nordbaden, the relatively higher
medication rate of patients without concomitant conduct disor-
der constitutes a peculiar difference compared to prescribing pat-
terns observed for children and adolescents. Though currently
the budgetary impact of adult ADHD seems moderate, this is
likely to change when physicians begin to recognize adult ADHD
more frequently, and once drugs for treatment of the condition
will have been licensed.
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OBJECTIVES: A budget impact model was used to estimate the
effect of introducing ziprasidone on acute bipolar mania drug-
related costs in Spain. METHODS: The model is based on
disease prevalence, incidence, drug use, adverse effects, drug
acquisition cost and sales forecasting data speciﬁc to Spain. It
takes the perspective of the Spanish National Pharmaceutical
budget and has a time horizon of 3 years. Drugs considered in
the study were lithium, valproate, olanzapine, risperidone, que-
tiapine, aripiprazole, haloperidol, lamotrigine, oxcarbazepine
and topiromate. Market shares for ziprasidone for the upcom-
ing three years were estimated at 9%, 14% and 17%. RESULTS:
